Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GEMFIBROZIL

All products: general benefit

Other products in the same Health Canada class (C10A, C10AB) — coverage varies; not interchangeable

  • Bezafibrate (Bezalip): general benefit
  • Fenofibrate (Lipidil): general benefit, Not a benefit
  • Clofibrate (Atromid-S): not a benefit
  • Atorvastatin (Lipitor): general benefit
  • Cholestyramine resin (Questran Light 4g Pk): general benefit, Not a benefit
  • Colesevelam (Lodalis): general benefit, Listing status unconfirmed

9 more in the class list below

Teva-Gemfibrozil · DIN 02241704 · 300mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-27 — choose a marketed DIN from the same-category list.Discontinued 2022-10-27 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-27 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-10-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Gemfibrozil · DIN 02241704 Manufacturer: Teva Canada Limited; listing date 2001-06-07 Health Canada: Cancelled post market since 2022-10-27 · brand TEVA-GEMFIBROZIL · ATC C10AB04 GEMFIBROZIL · form Capsule · route Oral · ingredients GEMFIBROZIL 300 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Gemfibrozil: Formulary list price $0.1340/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1340 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65364 · Verify on the e-Formulary ↗ (DIN 02241704)

Source record
DIN 02241704: Teva-Gemfibrozil Raw flags: chronicUseMed=Y, sec3=Y Item: 240600007; group id 305; item number 0667; lccId None; manufacturer id TEV Source form: Cap; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1340; ministry $0.1340 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241704 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65364
Interchangeable products
Apo-Gemfibrozil · DIN 01979574 · $0.1340 Lopid · DIN 00599026 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241704
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-10-27 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

CLOFIBRATE

· 2 products · Listed, not a benefit · strengths: 500mg · Cap

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS TEVA-GEMFIBROZIL (gemfibrozil tablet) is indicated in adults as an adjunct to diet and other therapeutic measures for: • Treatment of patients with very high serum triglyceride levels, Fredrickson classification Type IV and V hyperlipidemias, who are at high risk of sequelae and complications (i.e. pancreatitis) from their hyperlipidemia. • Treatment of patients with hypercholesterolemia, Type IIa and IIb mixed dyslipidemias, to regulate lipid levels (reduce serum triglycerides and LDL cholesterol levels and increase HDL cholesterol). TEVA-GEMFIBROZIL alone may not be adequate therapy in some patients with familial combined hyperlipidemia with Type IIb and IV hyperlipoproteinemia. Initial therapy for hyperlipidemia should include a specific diet, weight reduction, and an exercise program and for patients with diabetes mellitus, a good diabetic control. Gemfibrozil is not indicated for the treatment of Type I hyperlipoproteinemia. 1.1 Pediatrics Pediatrics (0 to >18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics No data is available. https://pdf.hres.ca/dpd_pm/00072920.PDF PM date: November 25, 1994 Source product: TEVA-GEMFIBROZIL; DIN 02142074; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.